Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab plus topical background therapy for moderate-to-severe atopic dermatitis
2021-002166-40Phase 3Completed
- Sponsor
- Galderma
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Nemolizumab plus topical background therapy with Placebo plus topical background therapy (2 arms). Primary endpoint: Proportion of subjects achieving EASI-75. Started Sep 2021; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2021-002166-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002166-40.